Chimin(SH:603222) Xin Lang Cai Jing·2025-04-29 01:23Core Insights - Jimin Health (603222.SH) reported a total revenue of 776 million yuan for 2024, ranking 64th among disclosed peers, which is a decrease of 119 million yuan or 13.28% year-on-year [1] - The company recorded a net profit attributable to shareholders of -59.71 million yuan, ranking 104th among peers [1] - Operating cash flow was 72.99 million yuan, ranking 86th, down 67.22 million yuan or 47.94% year-on-year [1] Financial Metrics - The latest debt-to-asset ratio is 35.05%, ranking 100th, an increase of 1.98 percentage points from the previous year [3] - The latest gross profit margin is 37.32%, ranking 90th [3] - Return on equity (ROE) is -4.03%, ranking 105th [3] - The diluted earnings per share is -0.11 yuan, ranking 103rd [3] - Total asset turnover is 0.32 times, ranking 67th, a decrease of 0.03 times or 7.96% year-on-year [3] - Inventory turnover is 3.16 times, down 0.93 times or 22.77% year-on-year [3] Shareholder Structure - The number of shareholders is 28,200, with the top ten shareholders holding 252 million shares, accounting for 47.99% of total equity [3] - The largest shareholder is Shuangge Group Co., Ltd., holding 24.3% [3] - Other significant shareholders include Zhang Xueqin (8.54%), Taizhou Ziming Trading Co., Ltd. (5.43%), and several others with smaller stakes [3] Research and Development - Total R&D expenditure is 41.61 million yuan, ranking 90th among peers [3] - The latest R&D expenditure ratio is 5.36%, ranking 97th [3]